Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study.

Rastinehad AR, Anastos H, Wajswol E, Winoker JS, Sfakianos JP, Doppalapudi SK, Carrick MR, Knauer CJ, Taouli B, Lewis SC, Tewari AK, Schwartz JA, Canfield SE, George AK, West JL, Halas NJ.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18590-18596. doi: 10.1073/pnas.1906929116. Epub 2019 Aug 26.

2.

Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency.

Clements MB, Schmidt KM, Canfield SE, Gilbert SM, Khandelwal SR, Koontz BF, Lallas CD, Liauw S, Nguyen PL, Showalter TN, Trabulsi EJ, Cathro HP, Schenkman NS, Krupski TL.

J Surg Educ. 2018 Mar - Apr;75(2):434-441. doi: 10.1016/j.jsurg.2017.08.012. Epub 2017 Oct 12.

PMID:
28923535
3.

Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-17.

Marconi L, MacLennan S, Lam TBL, Canfield SE, Yuan Y, Omar MI, N'Dow J, Sylvester R.

Eur Urol. 2017 Sep;72(3):e59-e60. doi: 10.1016/j.eururo.2017.06.006. Epub 2017 Jun 16. No abstract available.

PMID:
28629586
4.

Reply to Philipp Dahm, Vikram Narayan, and Jae Hung Jung's Letter to the Editor re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811-9.

Lam TBL, Sylvester RJ, Canfield SE, Marconi L, MacLennan S, Yuan Y, Omar MI, N'Dow J.

Eur Urol. 2017 Oct;72(4):e93-e94. doi: 10.1016/j.eururo.2017.04.008. Epub 2017 Apr 17. No abstract available.

PMID:
28427786
5.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.

PMID:
27939075
6.

Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree.

Sylvester RJ, Canfield SE, Lam TB, Marconi L, MacLennan S, Yuan Y, MacLennan G, Norrie J, Omar MI, Bruins HM, Hernández V, Plass K, Van Poppel H, N'Dow J.

Eur Urol. 2017 May;71(5):811-819. doi: 10.1016/j.eururo.2016.11.023. Epub 2016 Nov 30.

PMID:
27914898
7.

Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.

Gökce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D, Canfield SE, Pettaway CA.

Cancer. 2017 Feb 15;123(4):583-591. doi: 10.1002/cncr.30367. Epub 2016 Oct 11.

8.

Review: Newer and older drugs do not differ for lower urinary tract symptoms due to benign prostatic hyperplasia.

Foldes C, Canfield SE.

Ann Intern Med. 2016 Oct 18;165(8):JC45. doi: 10.7326/ACPJC-2016-165-8-045. No abstract available.

PMID:
27750305
9.

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.

PMID:
27349614
10.

Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus.

Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, Hora M, Powles T, Merseburger AS, Kuczyk MA, Bensalah K, Mulders PF, Ljungberg B, Lam TB.

Eur Urol. 2016 Aug;70(2):265-80. doi: 10.1016/j.eururo.2015.11.034. Epub 2015 Dec 23. Review.

PMID:
26707869
11.

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.

PMID:
26508312
12.

Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy.

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K, Canfield SE, Hora M, Kuczyk MA, Merseburger AS, Mulders PFA, Powles T, Staehler M, Ljungberg B, Volpe A.

Eur Urol. 2016 Apr;69(4):660-673. doi: 10.1016/j.eururo.2015.07.072. Epub 2015 Aug 29. Review.

PMID:
26323946
13.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW.

Rev Urol. 2014;16(4):172-80.

14.

Local treatments for metastases of renal cell carcinoma: a systematic review.

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A.

Lancet Oncol. 2014 Nov;15(12):e549-61. doi: 10.1016/S1470-2045(14)70235-9. Epub 2014 Oct 26. Review.

PMID:
25439697
15.

Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer.

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Dahm P, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.

Eur Urol. 2012 Dec;62(6):1097-117. doi: 10.1016/j.eururo.2012.07.028. Epub 2012 Jul 20. Review.

PMID:
22841673
16.

Corrigendum to "Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer" [Eur Urol 2012;61:972-93].

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group.

Eur Urol. 2012 Jul;62(1):193. doi: 10.1016/j.eururo.2012.04.003. Epub 2012 Apr 12. No abstract available.

PMID:
27989305
17.

ACP Journal Club. Radiation plus androgen deprivation therapy reduced mortality in locally advanced prostate cancer.

Canfield SE, Dahm P.

Ann Intern Med. 2012 Apr 17;156(8):JC4-05, JC4-04. doi: 10.7326/0003-4819-156-8-201204170-02005. No abstract available.

PMID:
22508745
18.

ACP Journal Club. Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer.

Canfield SE, Dahm P.

Ann Intern Med. 2012 Apr 17;156(8):JC4-04, JC4-05. doi: 10.7326/0003-4819-156-8-201204170-02004. No abstract available.

PMID:
22508744
19.

Systematic review of oncological outcomes following surgical management of localised renal cancer.

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.

Eur Urol. 2012 May;61(5):972-93. doi: 10.1016/j.eururo.2012.02.039. Epub 2012 Feb 25. Review. Erratum in: Eur Urol. 2012 Jul;62(1):193.

PMID:
22405593
20.

Sample size matters: A guide for urologists.

Hinh P, Canfield SE.

Indian J Urol. 2011 Oct;27(4):503-7. doi: 10.4103/0970-1591.91442.

21.

ACP Journal Club. Adding short-term androgen-deprivation therapy to radiotherapy improved survival in localized prostate cancer.

Canfield SE.

Ann Intern Med. 2011 Nov 15;155(10):JC5-07. doi: 10.7326/0003-4819-155-10-201111150-02007. No abstract available.

PMID:
22084354
22.

Health-related quality of life outcomes in Scandinavian patients after radical prostatectomy or watchful waiting: a critical appraisal.

Chan AA, Canfield SE, Wang R.

Asian J Androl. 2012 Jan;14(1):136-7. doi: 10.1038/aja.2011.162. Epub 2011 Nov 7. No abstract available.

23.

ACP Journal Club. Radical prostatectomy reduced mortality and disease progression over the long term more than watchful waiting in early prostate cancer.

Canfield SE.

Ann Intern Med. 2011 Jul 19;155(2):JC1-2. doi: 10.7326/0003-4819-155-2-201107190-02002. No abstract available.

PMID:
21768568
24.

Advanced topics in evidence-based urological oncology: using results of a subgroup analysis.

Scales CD Jr, Canfield SE.

Urol Oncol. 2011 Jul-Aug;29(4):462-6. doi: 10.1016/j.urolonc.2011.01.007. Review.

PMID:
21726797
25.

Advanced topics in evidence-based urologic oncology: surrogate endpoints.

Lavallée LT, Montori VM, Canfield SE, Breau RH.

Urol Oncol. 2011 Jul-Aug;29(4):447-53. doi: 10.1016/j.urolonc.2010.06.010. Review.

PMID:
21726795
26.

Introduction to a new series: advanced topics in evidence-based urologic oncology.

Canfield SE, Dahm P.

Urol Oncol. 2011 Jul-Aug;29(4):446. doi: 10.1016/j.urolonc.2010.03.015. No abstract available.

PMID:
21726794
27.

Recovery of erectile function after robotic prostatectomy: evidence-based outcomes.

Dahm P, Kang D, Stoffs TL, Canfield SE.

Urol Clin North Am. 2011 May;38(2):95-103. doi: 10.1016/j.ucl.2011.02.001. Review.

PMID:
21621076
28.

Combination therapy for erectile dysfunction: an update review.

Dhir RR, Lin HC, Canfield SE, Wang R.

Asian J Androl. 2011 May;13(3):382-90. doi: 10.1038/aja.2011.2. Epub 2011 Mar 21. Review.

29.

Rating the quality of evidence and the strength of recommendations using GRADE.

Canfield SE, Dahm P.

World J Urol. 2011 Jun;29(3):311-7. doi: 10.1007/s00345-011-0667-2. Epub 2011 Mar 9. Review.

PMID:
21387101
30.

Evidence-based urology in practice: randomized controlled trials stopped early for benefit.

Canfield SE, Sultan S, Dahm P; Evidence-Based Urology Working Group.

BJU Int. 2010 Oct;106(7):962-3. doi: 10.1111/j.1464-410X.2010.09542.x. Epub 2010 Aug 12. No abstract available.

31.

Assessment of the methodological quality of systematic reviews published in the urological literature from 1998 to 2008.

MacDonald SL, Canfield SE, Fesperman SF, Dahm P.

J Urol. 2010 Aug;184(2):648-53. doi: 10.1016/j.juro.2010.03.127. Epub 2010 Jun 19. Review.

PMID:
20639030
32.

The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review.

Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R.

Asian J Androl. 2010 Jul;12(4):500-8. doi: 10.1038/aja.2010.33. Epub 2010 May 17. Review.

33.

Evidence-based urology in practice: incorporating patient values in evidence-based clinical decision making.

Canfield SE, Dahm P; Evidence-Based Urology Working Group.

BJU Int. 2010 Jan;105(1):4-5. doi: 10.1111/j.1464-410X.2009.08939.x. Epub 2009 Oct 10. No abstract available.

34.

Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer.

Canfield SE.

Evid Based Med. 2009 Aug;14(4):104-5. doi: 10.1136/ebm.14.4.105. No abstract available.

PMID:
19648421
35.

Annual screening for prostate cancer did not reduce mortality from prostate cancer.

Canfield SE.

Evid Based Med. 2009 Aug;14(4):104-5. doi: 10.1136/ebm.14.4.104. No abstract available.

PMID:
19648420
36.

ACP Journal Club. Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer.

Canfield SE.

Ann Intern Med. 2009 Jun 16;150(12):JC6-5, JC6-4. No abstract available.

PMID:
19528550
37.

ACP Journal Club. Annual screening for prostate cancer did not reduce mortality from prostate cancer.

Canfield SE.

Ann Intern Med. 2009 Jun 16;150(12):JC6-4, JC6-5. No abstract available.

PMID:
19528549
38.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

39.

Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.

Canfield SE, Zhu K, Williams SA, McConkey DJ.

Mol Cancer Ther. 2006 Aug;5(8):2043-50.

40.
41.

Surveillance and management of recurrence for upper tract transitional cell carcinoma.

Canfield SE, Dinney CP, Droller MJ.

Urol Clin North Am. 2003 Nov;30(4):791-802. Review.

PMID:
14680315
42.

Closed suction or penrose drainage after partial nephrectomy: does it matter?

Sánchez-Ortiz R, Madsen LT, Swanson DA, Canfield SE, Wood CG.

J Urol. 2004 Jan;171(1):244-6.

PMID:
14665885
43.

IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach.

Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ.

Mol Ther. 2003 Feb;7(2):185-92.

44.
45.

Postradiation prostatic sarcoma: de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma?

Canfield SE, Gans TH, Unger P, Hall SJ.

Tech Urol. 2001 Dec;7(4):294-5. Review.

PMID:
11763492
46.

Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer.

Sanford MA, Yan Y, Canfield SE, Hassan W, Selleck WA, Atkinson G, Chen SH, Hall SJ.

Hum Gene Ther. 2001 Aug 10;12(12):1485-98.

PMID:
11506692

Supplemental Content

Loading ...
Support Center